Pfizer Stock Rises as 2025 Outlook in Line With Expectations

Group 1 - Pfizer affirmed its full-year 2024 projections, expecting revenue between $61 billion and $64 billion for both 2024 and 2025, with adjusted earnings per share (EPS) projected to grow in 2025 [1][2][3] - For 2024, adjusted EPS is projected to be between $2.75 and $2.95, aligning with analyst estimates of $63.01 billion in revenue and $2.93 EPS [2][3] - Pfizer successfully met its cost-cutting goal of $4 billion by the end of 2024, with an additional $500 million in savings expected over the next year [4][5] Group 2 - Pfizer's shares rose by 4.5% following the announcement, although they remain down approximately 8% for the year [6] - The company has returned to year-over-year revenue growth in its two most recent quarters for the first time since the peak of COVID vaccine sales [1][4]